sellWeak cluster of 210b5-1 plan
Charles McWherter sold $306k of CBAY
President of R&D at CymaBay Therapeutics, Inc.. 21,743 shares at an average of $14.07, traded Oct 18, 2023, filed Oct 18, 2023.
Warning score
27Value
$306k
21,743 shares
Holdings after
15,000
-59% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RolePresident
- +14Trade size$306k at market
- +20Share of holdings soldSold 59% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001062993-23-019549, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 18, 2023 | MOption exercise Common Stock | +21,743 | $5.00 | $109k | 36,743 | Oct 18, 2023 |
| Oct 18, 2023 | SOpen-market sale Common Stock10b5-1 | -21,743 | $14.07 | $306k | 15,000 | Oct 18, 2023 |
| Oct 18, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -10,401 | $0.00 | $0 | 0 | Oct 18, 2023 |
| Oct 18, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -708 | $0.00 | $0 | 1,412 | Oct 18, 2023 |
| Oct 18, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -236 | $0.00 | $0 | 470 | Oct 18, 2023 |
| Oct 18, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -3,892 | $0.00 | $0 | 7,782 | Oct 18, 2023 |
| Oct 18, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -6,506 | $0.00 | $0 | 13,010 | Oct 18, 2023 |
Related signals
Other insiders at CymaBay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $243k 11,332 shares | -57% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $110k 5,000 shares | -100% | |
| 32Weak | CymaBay Therapeutics, Inc. | Daniel Menold Vice President, Finance | $473k 21,497 shares | -215% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $120k 6,000 shares | -100% | |
| 40Moderate | CymaBay Therapeutics, Inc. | Sujal Shah Chief Executive Officer | $1.3M 64,865 shares | -28% | |
| 24Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $87k 5,000 shares | -100% | |
| 22Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $207k 11,342 shares | -43% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $107k 7,000 shares | -100% | |
| 40Moderate | CymaBay Therapeutics, Inc. | Sujal Shah Chief Executive Officer | $1.0M 64,863 shares | -30% | |
| 16Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $69k 5,000 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.